Effect of Benztropine on Haloperidol-Induced Prolactin Secretion

S. Lal, T. Mendis, P. Cervantes, H. Guyda and J.L. De Rivera

Departments of Psychiatry, Montreal General Hospital and McGill University; Douglas Hospital, and Protein and Polypeptide Laboratory, Montreal, PQ

Key Words. Prolactin • Cholinergic mechanisms • Benztropine • Haloperidol

Abstract. The effect of benztropine on haloperidol-induced prolactin secretion was investigated in 10 normal male volunteers. Benztropine had no effect on basal prolactin secretion but significantly enhanced the increase induced by haloperidol. The magnitude of the enhancement, however, was relatively small. These data suggest that in man cholinergic mechanisms have no effect on basal prolactin secretion but exert a weak inhibitory effect under conditions of dopamine receptor blockade. Differences in intrinsic anticholinergic properties may account for some of the variations in potency of different neuroleptics in increasing circulating prolactin concentrations.

Introduction

In previous work we found that in patients maintained on chronic neuroleptic therapy some of the groups had higher basal prolactin concentrations if they were also receiving concomitant anticholinergic antiparkinsonian drugs (De Rivera et al., 1976). Whereas there is evidence that cholinergic mechanisms modulate prolactin secretion in animals (Chen and Meites 1975; Gala et al., 1976; Subramanian and Gala, 1976; McLean and Nikitovitch-Winer, 1975), less information is available in man.

Neuroleptics show considerable variation in central anticholinergic potency (Snyder et al., 1974) and also in their capacity to stimulate prolactin secretion (Langer et al., 1977). Recently, it has been shown that clozapine, an effective antischizophrenic agent with potent central antimuscarinic properties (Miller and Hiley, 1974), has no (Sachar et al, 1976) or only weak stimulatory effects on prolactin secretion (Nair et al., 1978) in man. In order to investigate the possible role of anticholinergic mechanisms in neuroleptic-induced prolactin secretion, we have looked at the effect of benztropine, a muscarinic receptor-blocking agent, on haloperidol-induced prolactin secretion in normal subjects. Haloperidol was chosen because of its weak central antimuscarinic effects (Snyder et al., 1974).

Subjects and Methods

10 physically healthy, nonobese male volunteers, aged 21-50 years and on no medication, served as subjects. After an overnight fast, at 7:30-8:00 a.m., a 19-gauge scalp vein needle was inserted into an arm vein and kept open with heparin saline. 60 and 90 min after insertion of the needle (−45 and −15 min), baseline samples of blood were drawn. Immediately after the sample at −15 min, subjects received either benztropine mesylate (2 mg intramuscularly, Cogentin®) or saline intramuscularly. 15 min later, at time 0 min, the subjects were injected with haloperidol (1 mg intramuscularly, Haldol® or saline intramuscularly. Additional samples of blood were taken at 30, 60, 90, 120 and 150 min. Specimens were centrifuged and the serum stored at −20 °C until assayed.

---

1 This work was supported by grants from the Medical Research Council (Canada). Additional support was received from the G.W. Stairs Memorial Fund, McGill University and Merck Frosst Laboratories, PQ, Canada.
for prolactin by radio immunoassay (Hwang et al., 1971). Subjects remained recumbent throughout the procedure. Also, in view of the fact that prolactin secretion may increase during a daytime nap (Parker et al., 1973), subjects were asked to remain awake during the test session. Each of the 10 subjects was tested with benztropine plus haloperidol and saline plus haloperidol. 7 of the volunteers were also tested with benztropine plus saline and saline plus saline. The sequence of treatments was randomized. The interval between treatments was at least 72 h. Data were analyzed by factorial analysis of variance with repeated measurements and the paired t test.

**Results**

Haloperidol induced at least a twofold increase in prolactin above baseline values in 9 of the 10 subjects. The mean baseline concentration (samples at –45 and –15 min) was 6.3 ± 1.1 ng/ml (mean ± standard error of the mean), and this increased to a mean individual peak of 29.4 ± 6.7 ng/ml (range 11.5–80). When benztropine was given prior to injection of haloperidol, all 10 subjects showed at least a doubling of baseline concentrations. Values increased from 6.3 ± 0.8 to 37.7 ± 6.4 ng/ml (range 18–80). The mean prolactin concentrations after haloperidol were higher following benztropine pretreatment at each time interval (fig. 1), but none of the differences were statistically significant. Also, the difference in mean individual peak concentration was not statistically significant. However, when the data were analyzed by factorial analysis of variance, the prolactin concentrations for the 30 to 150 min sampling period were significantly higher when the subjects received benztropine prior to haloperidol than when they received saline prior to haloperidol (F1,36 = 16.4; p <0.001).

Prolactin concentrations following benztropine plus saline were not significantly different from those following saline plus saline (F1,72 = 0.38; NS).

7 of the subjects complained of restlessness and irritability (akathisia) after receiving haloperidol, and 2 other subjects appeared restless during the test though did not complain of this symptom. When pretreated with benztropine, these symptoms were abolished or considerably attenuated. Haloperidol with or without benztropine had a sedative effect in 7 of the subjects. No disfiguring side effects were reported after saline or benztropine in the absence of haloperidol.

**Discussion**

Neuroleptics increase prolactin secretion in animals (Clemens et al., 1974) and man (Langer et al., 1977). The prolactin-elevating potency correlates well, in general, with clinical neuroleptic potency (Langer et al., 1977) which in turn correlates with potency of dopamine receptor blockade (Seeman et al., 1976). In addition to dopaminergic modulation (Martin et al., 1974); cholinergic mechanisms may also play a role in prolactin secretion though this has been less well studied in man.

In the rat, the presence of a tuberoinfundibular cholinergic pathway has been described (Carson et al., 1977). Pilocarpine or physostigmine inhibit prolactin secretion (Chen and

![Fig. 1. Effect of benztropine on haloperidol-induced prolactin secretion. 10 male volunteers were injected with either haloperidol, 1 mg intramuscularly at time 0 min (○), or benztropine, 2 mg intramuscularly, 15 min before haloperidol (●). Each point represents the mean ± standard error of the mean. 7 of the subjects also received either benztropine alone (▲) or saline alone (△). The increase induced by haloperidol is significantly greater following benztropine pretreatment (p <0.001).](image-url)
Meites, 1975; Grandison and Meites, 1976), and atropine reverses the effect of pilocarpine in both the estrogen-primed male and the proestrous rat (Grandison and Meites, 1976). In the monkey, atropine has no effect on basal prolactin secretion but potentiates the elevation induced by perphenazine (Gala et al., 1976). These data are compatible with an inhibitory muscarinic-cholinergic mechanism. However, pilocarpine has no effect on neuroleptic-induced prolactin secretion in the rat (Grandison and Meites, 1976), and in the pseudopregnant animal there is evidence for a stimulatory cholinergic mechanism controlling the nocturnal surge of prolactin secretion (McLean and Nikitovitch-Winer, 1975). In man, neither physostigmine (Sachar et al., 1976) nor the muscarinic receptor agonist bethanechol (McCallum et al., 1976) affect basal prolactin secretion. Also, atropine has no effect on metoclopramide-induced prolactin secretion (McCallim et al., 1976).

In previous work, we found that some groups of patients who were receiving anticholinergic antiparkinsonian drugs in addition to chronic neuroleptic treatment had higher circulating prolactin concentrations than subjects on neuroleptics alone (De Rivera et al., 1976). However, following short-term administration of clozapine, a neuroleptic with potent antimuscarinic properties (Miller and Hiley, 1974), only a small increment in prolactin secretion was noted (Nair et al., 1978). In the present study, the antimuscarinic agent, benztropine, had no effect on basal prolactin secretion but significantly enhanced the elevation promoted by haloperidol. The magnitude of the increase in mean individual peak, however, was only 28%. These data suggest that in man cholinergic systems have no effect on basal prolactin secretion but may exert a weak inhibitory effect under conditions of dopamine receptor blockade. The results also suggest that differences in intrinsic anticholinergic properties may account for some of the variations in potency of different neuroleptics in inducing prolactin secretion. In addition, the weak ability of clozapine to induce prolactin secretion (Nair et al., 1978) cannot be explained on the basis of an inhibitory antimuscarinic effect of the drug.

It is unlikely that benzotropine enhances prolactin secretion by inhibiting haloperidol metabolism, as Gauthier et al. (1977), have shown that benzotropine decreases plasma levels of haloperidol.

Stress is known to increase prolactin secretion (Noel et al., 1972). In the present study, however, the subjects were less distressed after receiving haloperidol plus benzotropine than when they received haloperidol without benzotropine. Thus, a nonspecific stress effect is unlikely to account for differences observed in the present study.

References


Nair, N.P.V.; Lal, S.; Cervantes, P.; Yassa, R., and Gulya, H.: Effect of clozapine on apomorphine induced growth hormone secretion and serum prolactin concentrations in schizophrenia. Neuro-


Dr. S. Lal, Department of Psychiatry. Montreal General Hospital, Montreal, PQ H3G 1A4 (Canada)